Inactive Instrument

Chiasma, Inc.

Equities

CHMA

US16706W1027

Chiasma, Inc. Announces Management Changes

September 30, 2016 at 04:15 pm EDT

Chiasma, Inc. announced that Mark J. Fitzpatrick has been appointed President and Chief Executive Officer and a member of the company's Board of Directors, effective October 1, 2016. Mr. Fitzpatrick currently serves as Chiasma's Chief Financial Officer. He succeeds Mark Leuchtenberger, who has stepped down as Chief Executive Officer to pursue other opportunities.

Mr. Fitzpatrick joined Chiasma as its Chief Financial Officer in June 2015 and has over 25 years of experience in the biotechnology industry. He has held the senior-most financial leadership position and reported directly to the CEO of both public and private technology companies since 1991.

Latest news about Chiasma, Inc.

Chiasma, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	22-05-11	CI
Chiasma, Inc.(NasdaqGS:CHMA) dropped from S&P TMI Index	21-08-06	CI
Chiasma, Inc.(NasdaqGS:CHMA) dropped from S&P Global BMI Index	21-08-06	CI
Amryt Pharma : Completes Acquisition Of Chiasma	21-08-05	MT
Chiasma, Inc.(NasdaqGS:CHMA) dropped from NASDAQ Composite Index	21-08-05	CI
Chiasma, Inc.(NasdaqGS:CHMA) dropped from NASDAQ Biotechnology Index	21-08-05	CI
Amryt Pharma plc completed the acquisition of Chiasma, Inc. from MPM Capital and others.	21-08-04	CI
Transcript : Chiasma, Inc. - Shareholder/Analyst Call	21-08-03
Pulmatrix, Inc. Announces Board Changes	21-07-27	CI
Chiasma : Submits Marketing Authorization Application For Mycapssa in Europe	21-06-28	MT
Chiasma Announces Submission of Marketing Authorization Application for Mycapssa® to the European Medicines Agency	21-06-28	CI
Amryt Pharma : Sends Invitation To Shareholders To Vote For Chiasma Acquisition	21-06-28	MT
Chiasma, Inc.(NasdaqGS:CHMA) dropped from Russell 2500 Growth Index	21-06-25	CI
Chiasma, Inc.(NasdaqGS:CHMA) dropped from Russell 2000 Growth Index	21-06-25	CI
Chiasma, Inc.(NasdaqGS:CHMA) dropped from Russell Small Cap Completeness Index	21-06-25	CI
Chiasma, Inc.(NasdaqGS:CHMA) dropped from Russell Small Cap Comp Growth Index	21-06-25	CI
Chiasma, Inc.(NasdaqGS:CHMA) dropped from Russell 3000 Growth Index	21-06-25	CI
Chiasma, Inc.(NasdaqGS:CHMA) dropped from Russell 3000E Index	21-06-25	CI
Chiasma, Inc.(NasdaqGS:CHMA) dropped from Russell 2000 Index	21-06-25	CI
Chiasma, Inc.(NasdaqGS:CHMA) dropped from Russell 2000 Dynamic Index	21-06-25	CI
Chiasma, Inc.(NasdaqGS:CHMA) dropped from Russell 3000E Growth Index	21-06-25	CI
Chiasma, Inc.(NasdaqGS:CHMA) dropped from Russell 3000 Index	21-06-25	CI
Chiasma, Inc.(NasdaqGS:CHMA) dropped from Russell 2500 Index	21-06-25	CI
Chiasma, Inc. Presents Positive Patient-Reported Outcomes Data from Its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with Acromegaly	21-05-27	CI
Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences	21-05-20	CI

Chart Chiasma, Inc.

Duration

Period

More charts

Company Profile

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

Sector

More about the company